Primary and secondary carnitine insufficiency in adults and children, including newborns and infants. Secondary carnitine insufficiency in patients undergoing hemodialysis. Suspicion of secondary carnitine insufficiency in patients undergoing hemodialysis in the following cases: severe and persistent muscle spasms and / or hypotensive episodes during dialysis; energy deficit, which leads to a significant negative impact on the quality of life; muscle weakness and / or myopathy; cardiopathy; anemia that does not respond to treatment with erythropoietin or requires high doses of erythropoietin; loss of muscle mass.
Lecarnita solution Composition
active substance: levocarnitine
1 ml 200 mg levocarnitine
auxiliary substances: diluted hydrochloric acid, water for injection.
Lecarnita solution Dosage form
Basic physical and chemical properties:
clear solution from colorless to yellowish.
Lecarnita solution Pharmacological group
Amino acids and their derivatives. ATX code A16A A01.
Lecarnita solution Pharmacological properties.
Levocarnitine is present as a natural component in animal tissues, microorganisms and plants. In humans, the physiological needs for carnitine are replenished through the consumption of foods containing carnitine (primarily meat products), and through endogenous synthesis in the liver with trimethyl lysine. Only the L isomer is biologically active. Levocarnitine plays an important role in fat metabolism as well as in ketone body metabolism. Levocarnitine is necessary for the transport of long-chain fatty acids into mitochondria for their further beta-oxidation. By releasing coenzyme-A from thioesters, levocarnitine also enhances the oxidation of carbohydrates in the Krebs tricarboxylic acid cycle, also stimulates the activity of the key glycolysis enzyme – pyruvate dehydrogenase, and in skeletal muscle – oxidation of branched-chain amino acids. Thus, levocarnitine is directly or indirectly involved in most energy processes, its presence is necessary for the oxidation of fatty acids, amino acids, carbohydrates and ketone bodies. The highest concentration of levocarnitine is determined in muscle tissue, in the myocardium and liver. Levocarnitine plays an important role in cardiac metabolism, since the oxidation of fatty acids depends on the availability of a sufficient amount of this substance. Experimental studies have shown that under certain conditions, such as stress, acute ischemia, myocarditis, etc., it is possible to reduce the level of levocarnitine in myocardial tissue. A large number of animal studies have been carried out, which have confirmed the positive effect of levocarnitine in the case of various induced cardiac disorders: acute and chronic ischemia, cardiac decompensation, heart failure as a result of myocarditis, drug-induced cardiotoxicity (taxanes, adriamycin, etc.).
Levocarnitine is absorbed by the cells of the mucous membrane of the small intestine and enters the bloodstream relatively slowly, probably, absorption is associated with active
The absorbed levocarnitine is transported to various organs through the blood; it is believed that the transport system of erythrocytes is involved in the transport process.
Levocarnitine is excreted in the urine. The withdrawal rate is directly proportional to the concentration of carnitine in the blood.
Levocarnitine is practically not metabolized in the body.
Treatment of primary and secondary carnitine deficiency.
Secondary carnitine deficiency in patients undergoing hemodialysis.
Suspected secondary carnitine deficiency in patients undergoing hemodialysis in the following cases:
severe and persistent muscle spasms and / or hypotensive episodes during dialysis
energy deficiency, which leads to a significant negative impact on the quality of life
muscle weakness and / or myopathy
anemia, does not respond to erythropoietin treatment, or requires high doses of erythropoietin
loss of muscle mass.
Hypersensitivity to the components of the drug.